Based upon the known glycemic, cardiovascular, and body weight loss effects of GLP-1 receptor agonists in the treatment of T2DM and chronic weight management, we are conducting a clinical trial to expand this work by examining the effects of semaglutide on body composition, physical function and biomarkers of aging in older adults with prediabetes and well-controlled T2DM. Here, GLP1R is linked to type 2 diabetes mellitus.